Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB3 | Q13509 | 2/20 | 0.66 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.66 |
| ▸ | TUBB | P07437 | 1/20 | 0.66 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.66 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.66 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.66 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.66 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.66 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.66 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.66 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.66 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.66 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.66 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | MERTK | Q12866 | 3/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13412933 | 0.94 | TUBB3 (0.62) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13413775 | 0.92 | TUBB3 (0.63) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13412932 | 0.90 | TUBB3 (0.60) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13413773 | 0.89 | TUBB4A (0.66) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13413772 | 0.89 | TUBB4A (0.53) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13413760 | 0.89 | TUBB4A (0.66) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3119021 | 0.89 | TUBB4A (0.66) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13413776 | 0.88 | TUBB4A (0.52) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL3113048 | 0.87 | MERTK (0.70) | TUBB3TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13413784 | 0.87 | TUBB4A (0.64) | TUBB3TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | TUBB3 290/4885TUBB4A 160/4885TUBB 295/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB3 325/4885TUBB4A 155/4885TUBB 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.